Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Non-Current Assets (2016 - 2026)

Ocular Therapeutix has reported Non-Current Assets over the past 14 years, most recently at $26.5 million for Q1 2026.

  • For Q1 2026, Non-Current Assets rose 45.58% year-over-year to $26.5 million; the TTM value through Mar 2026 reached $94.3 million, up 32.78%, while the annual FY2025 figure was $25.9 million, 52.99% up from the prior year.
  • Non-Current Assets for Q1 2026 was $26.5 million at Ocular Therapeutix, up from $25.9 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $26.5 million in Q1 2026 and troughed at $12.7 million in Q2 2022.
  • A 5-year average of $19.2 million and a median of $19.1 million in 2024 define the central range for Non-Current Assets.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 71.35% in 2023 and later decreased 17.84% in 2024.
  • Year by year, Non-Current Assets stood at $19.7 million in 2022, then rose by 0.83% to $19.8 million in 2023, then decreased by 14.51% to $16.9 million in 2024, then skyrocketed by 52.99% to $25.9 million in 2025, then rose by 2.34% to $26.5 million in 2026.
  • Business Quant data shows Non-Current Assets for OCUL at $26.5 million in Q1 2026, $25.9 million in Q4 2025, and $23.9 million in Q3 2025.